Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated its Overweight rating on Ultragenyx Pharmaceutical, maintaining a price target of $116.
October 01, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Ultragenyx Pharmaceutical, maintaining a price target of $116.
The reiteration of an Overweight rating and a maintained price target of $116 by Cantor Fitzgerald is a positive signal for Ultragenyx Pharmaceutical. This suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100